Anthony Rostain1, Peter S Jensen2, Daniel F Connor3, Laura M Miesle4, Stephen V Faraone5. 1. University of Pennsylvania Health System, Philadelphia, USA rostain@mail.med.upenn.edu. 2. The REACH Institute, New York, NY, USA Mayo Clinic, Rochester, MN, USA. 3. University of Connecticut School of Medicine, Farmington, USA. 4. The JB Ashtin Group Inc., Plymouth, MI, USA. 5. SUNY Upstate Medical University, Syracuse, NY, USA.
Abstract
OBJECTIVE: Therapeutic goals for chronic mental disorders like major depressive disorder (MDD) and schizophrenia have evolved in parallel with the growing medical knowledge about the course and treatment of these disorders. Although the knowledge base regarding the clinical course of ADHD, a chronic psychiatric disorder, has evolved beyond symptomatic improvement and short-term treatment response, long-term goals, such as functional remission, have not yet been clearly defined. METHOD: A PubMed literature search was conducted to investigate the therapeutic goals of pharmacologic treatment referenced in the published literature from January 1998 through February 2010 using the following commonly used ADHD treatments as keywords: amphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine, and clonidine. This search was then combined with an additional search that included the following outcome keywords: remission, relapse, remit, response, normal, normalization, recovery, and effectiveness. RESULTS: Our search identified 102 publications. The majority (88.2% [90/102]) of these contained predefined criteria for treatment response. Predefined criteria for normalization and remission and/or relapse were presented in 4.9% (5/102), 12.7% (13/102), and 3.9% (4/102) of publications, respectively. There was a lack of consistency between the instruments used to measure outcomes as well as the criteria used to define treatment response, normalization, and remission as well as relapse. CONCLUSION: The therapeutic goals in treating ADHD should address optimal treatment outcomes that go beyond modest reductions of ADHD symptoms to include syndromatic, symptomatic, and functional remission. Future work should focus on reliable and valid tools to measure these outcomes in the clinical trial setting.
OBJECTIVE: Therapeutic goals for chronic mental disorders like major depressive disorder (MDD) and schizophrenia have evolved in parallel with the growing medical knowledge about the course and treatment of these disorders. Although the knowledge base regarding the clinical course of ADHD, a chronic psychiatric disorder, has evolved beyond symptomatic improvement and short-term treatment response, long-term goals, such as functional remission, have not yet been clearly defined. METHOD: A PubMed literature search was conducted to investigate the therapeutic goals of pharmacologic treatment referenced in the published literature from January 1998 through February 2010 using the following commonly used ADHD treatments as keywords: amphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine, and clonidine. This search was then combined with an additional search that included the following outcome keywords: remission, relapse, remit, response, normal, normalization, recovery, and effectiveness. RESULTS: Our search identified 102 publications. The majority (88.2% [90/102]) of these contained predefined criteria for treatment response. Predefined criteria for normalization and remission and/or relapse were presented in 4.9% (5/102), 12.7% (13/102), and 3.9% (4/102) of publications, respectively. There was a lack of consistency between the instruments used to measure outcomes as well as the criteria used to define treatment response, normalization, and remission as well as relapse. CONCLUSION: The therapeutic goals in treating ADHD should address optimal treatment outcomes that go beyond modest reductions of ADHD symptoms to include syndromatic, symptomatic, and functional remission. Future work should focus on reliable and valid tools to measure these outcomes in the clinical trial setting.
Authors: Sarah C O S Padilha; Suzane Virtuoso; Fernanda S Tonin; Helena H L Borba; Roberto Pontarolo Journal: Eur Child Adolesc Psychiatry Date: 2018-02-19 Impact factor: 4.785
Authors: Asha Hareendran; Juliana Setyawan; Robin Pokrzywinski; Anna Steenrod; Manisha Madhoo; M Haim Erder Journal: Health Qual Life Outcomes Date: 2015-08-22 Impact factor: 3.186
Authors: Steven R Pliszka; Timothy E Wilens; Samantha Bostrom; Valerie K Arnold; Andrea Marraffino; Andrew J Cutler; Frank A López; Norberto J DeSousa; Floyd R Sallee; Bev Incledon; Jeffrey H Newcorn Journal: J Child Adolesc Psychopharmacol Date: 2017-07-21 Impact factor: 2.576
Authors: Timothy E Wilens; Stephen V Faraone; Paul G Hammerness; Steven R Pliszka; Cassandra L Uchida; Norberto J DeSousa; Floyd R Sallee; Bev Incledon; Jeffrey H Newcorn Journal: J Atten Disord Date: 2021-06-04 Impact factor: 3.256